Mononine Related Published Studies
Well-designed clinical trials related to Mononine (Coagulation Factor IX Human)
A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. [2011.02]
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. [2010.08.10]
Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. [2010.04.30]
Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. [2010]
Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. [2009.10.01]
Well-designed clinical trials possibly related to Mononine (Coagulation Factor IX Human)
Vascular effects of ultrafine particles in persons with type 2 diabetes. [2010.12]
Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study. [2010.11]
Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. [2010.10.01]
Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. [2010.06.20]
Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. [2010.03]
Phosphorylcholine-coated circuits improve preservation of platelet count and reduce expression of proinflammatory cytokines in CABG: a prospective randomized trial. [2009.07]
Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors. [2008.07]
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. [2008.06.03]
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. [2008.05]
Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. [2008.04]
p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer. [2008.04]
Far infrared therapy inhibits vascular endothelial inflammation via the induction of heme oxygenase-1. [2008.04]
Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. [2008.03]
A heparin-bonded vascular graft generates no systemic effect on markers of hemostasis activation or detectable heparin-induced thrombocytopenia-associated antibodies in humans. [2008.02]
Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study. [2008]
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. [2007.12.04]
Prevention of haemophilic synovitis: prophylaxis. [2007.11]
Dosing factor VIIa (recombinant) in nonhemophiliac patients with bleeding after cardiac surgery. [2007.09.01]
A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. [2007.09]
Warfarin cessation before cardiopulmonary bypass: lessons learned from a randomized controlled trial of oral vitamin K. [2007.07]
Comparison of the effects of tibolone and estrogen therapy on hemostasis in surgical menopause: a randomized, double-blind, placebo-controlled study. [2007.04]
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. [2007.01.15]
Other research related to Mononine (Coagulation Factor IX Human)
The first recombinant FVIII produced in human cells--an update on its clinical
development programme. [2014]
A Phase 2, randomized, partially blinded, active-controlled study assessing the
efficacy and safety of variable anticoagulation reversal using the REG1 system in
patients with acute coronary syndromes: results of the RADAR trial. [2013]
Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. [2011.07.15]
Basic hemostatic parameters in patients with long-term oral anticoagulation undergoing cholecystectomy. [2011.06]
Self-management of oral anticoagulation therapy--methodological and clinical aspects. [2011.05]
International normalized ratio versus plasma levels of coagulation factors in patients on vitamin K antagonist therapy. [2011.04]
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. [2011.01]
Safety and efficacy of plasma-derived coagulation factor IX concentrate (AlphaNine(R) SD) in patients with haemophilia B undergoing surgical intervention: a single institution retrospective analysis. [2011.01]
A new drug form of blood coagulation factor IX: red blood cell-entrapped factor IX. [2010.10]
[Analysis of thirteen cases with secondary coagulation disorder caused by raticide exposure]. [2010.08]
Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? [2010.07]
Discard tubes are not necessary when drawing samples for specialized coagulation testing. [2010.04]
Venous thrombosis of the upper extremity: effect of blood group and coagulation factor levels on risk. [2010.04]
Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. [2010.03]
Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. [2010.03]
First clinical application of an actively reversible direct factor IXa inhibitor
as an anticoagulation strategy in patients undergoing percutaneous coronary
intervention. [2010]
Effects of soy consumption on oxidative stress, blood homocysteine, coagulation factors, and phosphorus in peritoneal dialysis patients. [2009.09]
Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6 degrees C storage. [2009.08]
Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. [2009.07.23]
Thrombin generation and coagulation factor activities: evaluation and comparison with the international normalized ratio. [2009.07]
Prospective longitudinal study of coagulation profiles in children with hypoplastic left heart syndrome from stage I through Fontan completion. [2009.04]
Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. [2009.02.26]
Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. [2009.01]
L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. [2008.08]
Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effect on coagulation factor testing. [2008.07]
Hydrolysis of coagulation factors by circulating IgG is associated with a reduced risk for chronic allograft nephropathy in renal transplanted patients. [2008.06.15]
Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. [2008.05]
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. [2008.04]
The neonatal coagulation system and the vitamin K deficiency bleeding - a mini review. [2008]
Change of coagulation parameters after double plateletpheresis. [2007.10]
Successful emergency reversal of phenprocoumon anticoagulation with prothrombin complex concentrate: a prospective clinical study. [2007.09]
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. [2007.08]
Other possibly related research studies
Secondary prophylaxis with factor IX concentrates: continuous infusion. [2008.09]
Comparing oxygen-sensitive MRI (BOLD R2*) with oxygen electrode measurements: a pilot study in men with prostate cancer. [2009.09]
Therapeutic properties and safety of recombinant factor VIII and factor IX. [2009.06]
Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B. [2009.07.30]
Cellular immune response to cryptic epitopes during therapeutic gene transfer. [2009.06.30]
Improved peptide prodrugs of 5-ALA for PDT: rationalization of cellular accumulation and protoporphyrin IX production by direct determination of cellular prodrug uptake and prodrug metabolization. [2009.07.09]
Increased platelet glycoprotein Ib receptor number, enhanced platelet adhesion and severe cerebral ischaemia in a patient with polycythaemia vera. [2009.06]
Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. [2009.06]
Acute and chronic in vivo therapeutic resistance. [2009.06.01]
Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. [2009.07.23]
ITI with high-dose FIX and combined immunosuppressive therapy in a patient with severe haemophilia B and inhibitor. [2009.05]
Treatment selection for patients with metastatic renal cell carcinoma. [2009.05.15]
Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg. [2009.07.01]
Failure of recombinant factor VIIa to correct the coagulopathy in a case of severe postpartum hemorrhage. [2009.04]
Differences in immune response may explain lower survival among older men with pneumonia. [2009.05]
Gene therapy for hemophilia: clinical trials and technical tribulations. [2009.02]
Host and vector-dependent effects on the risk of germline transmission of AAV vectors. [2009.06]
Plasma fractionation issues. [2009.04]
Improved treatment feasibility in children with hemophilia using arteriovenous fistulae: the results after seven years of follow-up. [2009.05]
Endovascular abdominal aortic aneurysm repair in a patient with severe hemophilia B. [2009.02]
Acquired hemophilia first manifesting as life-threatening intracranial hemorrhage: case report. [2009.02]
Induction of immune tolerance to FIX following muscular AAV gene transfer is AAV-dose/FIX-level dependent. [2009.05]
Effects of high dose oestrogen therapy on circulating inflammatory markers. [2009.03.20]
New anticoagulants - towards the development of an "ideal" anticoagulant. [2009.02]
Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. [2009.06]
Hepatocyte growth factor prevents multiple organ injuries in endotoxemic mice through a heme oxygenase-1-dependent mechanism. [2009.03.06]
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. [2009]
The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. [2009.01.27]
Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. [2009.01]
Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density. [2009.01]
Central venous access devices for paediatric patients with haemophilia: a single-institution experience. [2009.01]
Familial deficiency of vitamin K-dependent clotting factors. [2008.11]
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? [2008.11]
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors? [2008.11]
Thrombophilic risk factors in epileptic children treated with valproic Acid. [2009.02]
High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. [2009.01]
Secondary prophylaxis in adolescent and adult haemophiliacs. [2008.09]
Barriers to primary prophylaxis in haemophilic children: the issue of the venous access. [2008.09]
Primary prophylaxis in children with haemophilia. [2008.09]
[Refractory acquired hemophilia A in which factor VIII inhibitor was not detected at onset and thereafter deteriorated after total hip replacement arthroplasty] [2008.11]
Children's preferences of transfer devices for reconstitution of factors VIII and IX for the treatment of haemophilia. [2009.01]
Understanding the therapeutic action of recombinant factor VIIa in platelet disorders. [2008.12]
|